العلاج المساعد للميلانوما الجلدية AJCC8 من المرحلة IIB–IIC المُستأصلة بالكامل لدى المرضى الذين تبلغ أعمارهم 12 عامًا فما فوق

References

DOI: 10.1016/j.annonc.2024.11.006

1. In June 2022, the EMA approved the use of adjuvant pembrolizumab for patients 12 years old with stage IIB-IIC melanoma following complete resection.
2. Adjuvant therapy with either pembrolizumab [ESMO-MCBS v1.1 score: A] or nivolumab [ESMO-MCBS v1.1 score: A] for 12 months should be considered for patients with stage IIB-IIC disease; treatment discussions with the patient should include consideration of the RFS benefit but lack of mature OS data [I, A].
3. In the KEYNOTE-716 trial, 976 patients (age 12 years) with completely resected AJCC8 pathological stage IIB-IIC melanoma received intravenous pembrolizumab 200 mg (2 mg/kg in paediatric patients) or placebo every 3 weeks (q3w) for 17 cycles or until disease recurrence or unacceptable toxicity.